IS7189A - Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra - Google Patents

Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra

Info

Publication number
IS7189A
IS7189A IS7189A IS7189A IS7189A IS 7189 A IS7189 A IS 7189A IS 7189 A IS7189 A IS 7189A IS 7189 A IS7189 A IS 7189A IS 7189 A IS7189 A IS 7189A
Authority
IS
Iceland
Prior art keywords
somatostatin
diagnosis
treatment
bombesin analogues
bombesin
Prior art date
Application number
IS7189A
Other languages
English (en)
Inventor
H. Coy David
A. Fuselier Joseph
A. Murphy William
Sun Lichun
Original Assignee
The Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund
Publication of IS7189A publication Critical patent/IS7189A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Percussion Or Vibration Massage (AREA)
IS7189A 2001-09-21 2004-03-19 Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra IS7189A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32385101P 2001-09-21 2001-09-21
PCT/US2002/030143 WO2003028527A2 (en) 2001-09-21 2002-09-20 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof

Publications (1)

Publication Number Publication Date
IS7189A true IS7189A (is) 2004-03-19

Family

ID=23260992

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7189A IS7189A (is) 2001-09-21 2004-03-19 Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra

Country Status (16)

Country Link
US (1) US7326685B2 (is)
EP (1) EP1435826A4 (is)
JP (1) JP4799820B2 (is)
KR (1) KR20040047846A (is)
CN (1) CN1589151A (is)
AU (1) AU2002341792B2 (is)
BR (1) BR0212897A (is)
CA (1) CA2461099A1 (is)
IL (2) IL160993A0 (is)
IS (1) IS7189A (is)
MX (1) MXPA04002621A (is)
NO (1) NO20041186L (is)
NZ (1) NZ532204A (is)
PL (1) PL369336A1 (is)
WO (1) WO2003028527A2 (is)
ZA (1) ZA200402698B (is)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6721705B2 (en) * 2000-02-04 2004-04-13 Webley Systems, Inc. Robust voice browser system and voice activated device controller
DE60331049D1 (de) * 2002-03-01 2010-03-11 Univ Tulane Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden
US8060626B2 (en) * 2008-09-22 2011-11-15 Sony Computer Entertainment America Llc. Method for host selection based on discovered NAT type
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
US8709998B2 (en) * 2003-04-22 2014-04-29 Ipsen Pharma S.A.S. Peptide vectors
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
WO2005002672A2 (en) * 2003-07-01 2005-01-13 President And Fellows Of Harvard College Sirt1 modulators for manipulating cells/organism lifespan/stress response
CA2548671C (en) 2003-12-29 2015-02-24 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050255045A1 (en) * 2004-05-13 2005-11-17 Woltering Eugene A Surgical marking composition and method
EP1744787A4 (en) * 2004-05-14 2011-04-06 Interface Biologics Inc POLYMER COUPLING AGENTS AND PHARMACEUTICALLY ACTIVE POLYMERS MANUFACTURED THEREOF
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
WO2006007411A2 (en) * 2004-06-16 2006-01-19 President And Fellows Of Harvard College Methods and compositions for modulating bax-mediated apoptosis
WO2006004722A2 (en) * 2004-06-30 2006-01-12 Biomol Research Laboratories, Inc. Compositions and methods for selectively activating human sirtuins
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
CN102772358A (zh) * 2005-06-16 2012-11-14 美瑞德生物工程公司 药物组合物及其用途
JP5116468B2 (ja) * 2006-02-23 2013-01-09 株式会社Ａｄｅｋａ 診断用マーカー
DE102006035083A1 (de) * 2006-07-28 2008-01-31 medac Gesellschaft für klinische Spezialgeräte mbH Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
US7960342B2 (en) 2006-10-16 2011-06-14 The Salk Institute For Biological Studies Receptor(SSTR2)-selective somatostatin antagonists
US8691761B2 (en) * 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
MX2009004178A (es) 2006-10-20 2009-09-07 Ipsen Pharma Sas Conjugados peptidicos citotoxicos.
EP2144888A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHODS OF TREATING CANCER
KR20100016385A (ko) * 2007-04-10 2010-02-12 미리어드 파마슈티칼스, 인코포레이티드 뇌종양 치료방법
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
EP2144886A4 (en) * 2007-04-10 2012-10-03 Myrexis Inc METHOD OF TREATING MELANOMA
AU2008236995A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Dosages and methods for the treatment of cancer
US9358272B2 (en) * 2011-02-17 2016-06-07 The Administrators Of The Tulane Educational Fund Multicomponent compositions and their uses
WO2014153164A1 (en) 2013-03-14 2014-09-25 The California Institute For Biomedical Research Targeting agent antibody conjugates and uses thereof
CN109104863A (zh) 2016-02-09 2018-12-28 克德瑞德风险投资公司 生长抑素受体拮抗剂化合物及其使用方法
AU2017238246B2 (en) 2016-03-24 2021-04-01 The Administrators Of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses
WO2019148294A1 (en) 2018-02-02 2019-08-08 Interface Biologics, Inc. Dimeric dexamethasone prodrug compositions and uses thereof
US20210000988A1 (en) * 2018-03-15 2021-01-07 Osaka University Pharmaceutical composition containing 211at-labeled amino acid derivative, and method for producing said pharmaceutical composition
WO2021220061A2 (en) 2020-05-01 2021-11-04 Ripple Therapeutics Corporation Heterodimer compositions and methods for the treatment of ocular disorders

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904642A (en) 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US5073541A (en) 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
US5753627A (en) 1988-12-05 1998-05-19 Novartis Ag Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5633263A (en) 1989-04-26 1997-05-27 The Administrators Of The Tulane Educational Fund Linear somatostatin analogs
CA2032499C (en) 1989-07-20 2002-05-14 Rainer Albert Polypeptide derivatives
DK0450480T3 (da) * 1990-04-06 1995-08-14 Univ Tulane Somatostatinaloger
US5443815A (en) 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5411943A (en) 1992-02-25 1995-05-02 Biomeasure, Inc. Hepatoma treatment with somatostatin analogs
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5597894A (en) 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
US5770687A (en) 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
US6051554A (en) * 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5708135A (en) 1995-09-29 1998-01-13 Biomeasure Incorporated Cyclic peptide analogs of somatostatin
US5750499A (en) 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US5843903A (en) 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
US6156725A (en) * 1996-08-16 2000-12-05 National Institute Of Immunology Drug for the treatment of cancer
DE69840647D1 (de) 1997-04-22 2009-04-23 Curator Of The University Of M Konjugate aus peptiden, die liganden von gastrinrezeptoren sind
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
ATE424414T1 (de) * 2001-06-08 2009-03-15 Sod Conseils Rech Applic Chimere somatostatin-dopamin-analoga

Also Published As

Publication number Publication date
US20050070470A1 (en) 2005-03-31
WO2003028527A3 (en) 2003-10-30
NO20041186L (no) 2004-05-05
IL160993A (en) 2011-04-28
NZ532204A (en) 2006-04-28
AU2002341792B2 (en) 2007-09-06
EP1435826A4 (en) 2009-07-15
MXPA04002621A (es) 2004-07-08
PL369336A1 (en) 2005-04-18
CN1589151A (zh) 2005-03-02
CA2461099A1 (en) 2003-04-10
EP1435826A2 (en) 2004-07-14
IL160993A0 (en) 2004-08-31
US7326685B2 (en) 2008-02-05
ZA200402698B (en) 2005-04-25
WO2003028527A8 (en) 2004-04-15
KR20040047846A (ko) 2004-06-05
JP4799820B2 (ja) 2011-10-26
WO2003028527A2 (en) 2003-04-10
JP2005505580A (ja) 2005-02-24
BR0212897A (pt) 2004-08-24

Similar Documents

Publication Publication Date Title
IS7189A (is) Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra
DK1404809T3 (da) Forbedrede hudsubstitutter og anvendelser deraf
DE60237823D1 (de) Medizinisches behandlungsinstrument
NO20030832D0 (no) Kondenserte cykliske forbindelser og medisinsk anvendelse derav
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
NO20051503D0 (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
NO20035156D0 (no) Fremgangsmåter for brönnbehandling
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
NO20034159D0 (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
HK1061212A1 (en) Pyranoindazoles and their use for the treatment ofglaucoma
FR2846545B1 (fr) Implant d'osteosynthese intramedullaire
IL157328A0 (en) Treatment involving dkk-1 or antagonists thereof
DE60205718D1 (de) Flexibler wellschlauch und anschlussverfahren
DE60223576D1 (de) Hautbehandlungszusammensetzung
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
DE60220220D1 (de) Blutbehandlungssystem
DE60227963D1 (de) Behandlungssystem
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
DE60222664D1 (de) Hautbehandlungsmittel
SG106109A1 (en) Tomography or curved surfaces
DE60114244D1 (de) Osteosynthesevorrichtung
DE50209299D1 (de) Chirurgisches schälmesser
DE60228736D1 (de) Menschliches bmcc1-gen
GB0303016D0 (en) Science technology and invention processor version 1.0.
FI5249U1 (fi) Kantojenkäsittelylaitteisto